Risedronate Sodium

製品コードS1428 バッチS142802

印刷

化学情報

Chemical Structure Synonyms NE 58095 Sodium Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C7H10NNaO7P2
分子量 305.09 CAS No. 115436-72-1
Solubility (25°C)* 体外 Water 2 mg/mL (6.55 mM)
DMSO Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Risedronate (NE 58095) sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.
in vitro Risedronate causes a total inhibition of colony formation whereas Etidronate has relatively little effect in calcifying fibroblastic colony-forming unit (CFU-f) cultures of rat bone marrow cells in vitro. Risedronate (1 μM) decreases the formation of colonies displaying osteoblastic characteristics such as alkaline phosphatase expression, collagen accumulation, and calcification. Risedronate (1 nM) and alendronate increases the formation of fibroblastic colonies, suggesting a mild anabolic effect, however, the formation of colonies with osteoblastic properties is not affected. [1] Risedronate significantly inhibits expression of c-Fos and nuclear factor of activated T cells (NFAT) c1 induced by RANKL in bone marrow-derived macrophages (BMMs). [2]
in vivo Risedronate (1 mg/kg) significantly increases the volumetric densities of bone (Vb) and osteoblast Vob and decreases Vm more prominently in rats. [3] Risedronate causes a significant and dose-dependent reduction of tooth movement after the orthodontic force is applied in rats. [4] Risedronate prevents a reduction in periosteal bone formation and an increase in endocortical bone erosion, resulting in prevention of alterations in percent cortical bone and marrow areas. Risedronate increases osteocyte density and lacunar occupancy and prevented a GC-induced increase in cortical porosity. Risedronate and Vitamin K(2) has additive effects on osteocyte density and lacunar occupancy and a synergistic effect on cortical porosity. [5]

プロトコル(参考用のみ)

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization [ Cell Rep Methods, 2023, 3(10):100599] PubMed: 37797618
The intrasulcular application effect of bisphosphonate hydrogel toward osteoclast activity and relapse movement [ Saudi Dent J, 2021, 33(5):292-298] PubMed: 34194193

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。